Secukinumab for psoriasis in a patient with hepatitis B
Published Web Locationhttps://doi.org/10.5070/D3249041421
The case reported describes a 48-year-old man with congenital hepatitis B receiving secukinumab for treatment of psoriasis. Some biologic therapies have been associated with an increased risk of reactivation of hepatitis B. In the case of this patient, secukinumab has successfully managed his psoriasis without evidence of hepatitis B virus reactivation.